

Elazar Rabbani et al.
Serial No.: 08/978,637
Filed: November 25, 1997
Page 2 [Amendment Under 37 C.F.R. §1.115 (UR) Response
to the February 16, 1999 Office Action - August 17, 1999]



PLEASE AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:

In The Specification:

Page 1, line 1, insert the following:

--CROSS-REFERENCE TO RELATED APPLICATIONS

D / This application is a divisional application of U.S. Patent Application Serial No. 08/574,443, filed on December 15, 1995, now abandoned.

Page 9, line 13, after "reimportation to the" and before "as snRNPs" change "cytoplasm" to -- nucleus -- .

Page 64, line 14, after "phosphate buffered" and before "to reconstitute" change "salint" to -- saline -- .

Page 81, line 7, after "i.e., a cell" and before "of processing RNA by" change "capable" to -- incapable -- .

Page 105, line 2, after "number of" and before "entities" change "procuct" to -- product -- .

Page 109, line 5, change the first word in this line before "synthesis" from "intracellular" to -- intracellular -- .

Page 114, line 7, after "by which the" and before "agent binds" change "dislocaton" to -- dislocation -- .

Page 123, line 7, change the penultimate word in this line from "shwon" to -- shown -- .



Elazar Rabbani et al.

Serial No.: 08/978.637

Filed: November 25, 1997

Page 3 [Amendment Under 37 C.F.R. 311 & 1515.14] In Response

[REDACTED] to the February 16, 1999 Office Action - August 17, 1999]

Page 127, last line, change the first word in this line from "stepavidin"

to -- streptavidin -- .

~~Page 134, lines 6, 9 and 10, change the spelling of "CNMAC"~~

to -- CHENAC -- in all three instances.

~~Page 151, line 8, change the first word in this line from "complimentary"~~

to -- complementary -- .

~~Page 159, line 11, delete the last word in this line "structures" which is~~

duplicative of the previous word.

Page 180, line 8, after "assay of the" and before "of the U1" change

"affect" to -- effect

Page 181, line 4, after "CD8-coated" and before "Flasks" change

"(CELLector™" to ->(CELLector™) - .

72

In The Claims:

Cancel claims 2-24.

Amend claims 247, 249, 251, 253, 254, 256, 259, 268, 273, 278, 279, 283,

289, 302, 303 and 312 as follows:

~~247 (Amended) The composition of claim 245, wherein said primary nucleic acid component is selected from the group consisting of a nucleic acid, a nucleic acid construct, a nucleic acid conjugate, a virus, viral fragment, a viral vector, a viroid, a phage, [a phage,] a plasmid, a plasmid vector, a bacterium, [and] a bacterial fragment, [or] and a combination of the foregoing.~~

249. (Amended) The composition of claim 245, wherein said primary nucleic acid component is selected from the group consisting of DNA, RNA, [and] nucleic acid analogs, [or] and a combination thereof.



D5

251. (Amended) The composition of claim 245, wherein said secondary nucleic acid component or said tertiary nucleic acid component is selected from the group consisting of DNA, RNA, a DNA-RNA hybrid, [and] a DNA-RNA chimera, [or] and a combination of the foregoing.

D6

253. (Amended) The composition of claim 252, wherein said signal processing sequence is selected from the group consisting of a promoter, an initiator, a terminator, an intron, [and] a cellular localization element, [or] and a combination of the foregoing.

D7

254. (Amended) The composition of claim 252, wherein said signal processing element is contained in an element selected from the group consisting of said primary nucleic acid component, said secondary nucleic acid component, said nucleic acid product, [and] said tertiary nucleic acid component, [or] and a combination of the foregoing.

D8

259. (Amended) The composition of claim 258, wherein said vector is selected from the group consisting of a viral vector, a phage vector, [and] a plasmid vector, [or] and a combination thereof.

D9

Claim 265, penultimate line, delete the second occurrence of "localizing".

268. (Amended) The composition of claim 265, wherein said nucleic acid of interest (ii) is selected from the group consisting of DNA, RNA, a DNA-RNA hybrid, [and] a DNA-RNA chimera, [or] and a combination of the foregoing.



D10 273. (Amended) The composition of claim 265, wherein said non-natural nucleic acid product is selected from the group consisting of antisense RNA, antisense DNA, sense RNA, sense DNA, a ribozyme, [and] a protein binding nucleic acid sequence, [or] and a combination of the foregoing.

D11 278. (Amended) The composition of claim 265, wherein said nucleic acid component is selected from the group consisting of a nucleic acid, a nucleic acid construct, a nucleic acid conjugate, a virus, viral fragment, a viral vector, a viroid, a phage, [a phage,] a plasmid, a plasmid vector, a bacterium, [and] a bacterial fragment, [or] and a combination of the foregoing.

D11 279. (Amended) The composition of claim 278, wherein said nucleic acid is selected from the group consisting of DNA, RNA, a DNA-RNA hybrid, [and] a DNA-RNA chimera, [or] and a combination of the foregoing.

D12 283. (Amended) The composition of claim 282, wherein said vector is selected from the group consisting of a viral vector, a phage vector, [and] a plasmid vector, [or] and a combination thereof.

D13 289. (Amended) The biological system of claim 288, wherein said system is selected from the group consisting of an organism, an organ, a tissue, [and] a culture, [or] and a combination thereof.

D14 302. (Amended) The composition of claim 299, wherein said component is derived or selected from the group consisting of a nucleic acid, a nucleic acid construct, a nucleic acid conjugate, a virus, viral fragment, a viral vector, a viroid, a phage, [a phage,] a plasmid, a plasmid vector, a bacterium, [and] a bacterial fragment, [or] and a combination of the foregoing.

D14 303. (Amended) The composition of claim 299, wherein said nucleic acid is selected from the group consisting of DNA, RNA, [and] nucleic acid analogs, [or] and a combination thereof.

Elazar Rabbani et al.
Serial No.: 08/978,637
Filed: November 25, 1997
Page 6 [Amendment Under 37 C.F.R. §1.115 in Response
to the February 16, 1999 Office Action - August 17, 1999]



312. (Amended) The composition of claim 299, wherein said specific nucleic acid products are selected from the group consisting of antisense RNA, antisense DNA, a ribozyme, [and] a protein binding nucleic acid sequence, [or] and a combination of the foregoing.

D/5

* * * * *